Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study-Reference-Cited by-同舟云学术

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Published:2013-08 Issue:8 Volume:12 Page:756-767
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Selmaj Krzysztof,Li David KB,Hartung Hans-Peter,Hemmer Bernhard,Kappos Ludwig,Freedman Mark S,Stüve Olaf,Rieckmann Peter,Montalban Xavier,Ziemssen Tjalf,Auberson Lixin Zhang,Pohlmann Harald,Mercier Francois,Dahlke Frank,Wallström Erik

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference11 articles.

1. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology;Brinkmann;Pharmacol Ther,2007

2. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis;Brinkmann;Nat Rev Drug Discov,2010

3. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation;Choi;Proc Natl Acad Sci USA,2011

4. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators;Soliven;Neurology,2011

5. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”;Polman;Ann Neurol,2005

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siponimod-associated cystoid macular edema without known risk factors;American Journal of Ophthalmology Case Reports;2024-12

2. Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia;Frontiers in Immunology;2024-06-17

3. Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-05

4. Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis;Sclerosis;2024-04-01

5. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study;Clinical Pharmacology in Drug Development;2024-03-05